| Literature DB >> 26919761 |
Matthew Volgraf, Benjamin D Sellers, Yu Jiang1, Guosheng Wu1, Cuong Q Ly, Elisia Villemure, Richard M Pastor, Po-wai Yuen1, Aijun Lu1, Xifeng Luo1, Mingcui Liu1, Shun Zhang1, Liang Sun1, Yuhong Fu1, Patrick J Lupardus, Heidi J A Wallweber, Bianca M Liederer, Gauri Deshmukh, Emile Plise, Suzanne Tay, Paul Reynen, James Herrington, Amy Gustafson, Yichin Liu, Akim Dirksen2, Matthias G A Dietz2, Yanzhou Liu, Tzu-Ming Wang, Jesse E Hanson, David Hackos, Kimberly Scearce-Levie, Jacob B Schwarz.
Abstract
The N-methyl-D-aspartate receptor (NMDAR) is a Na(+) and Ca(2+) permeable ionotropic glutamate receptor that is activated by the coagonists glycine and glutamate. NMDARs are critical to synaptic signaling and plasticity, and their dysfunction has been implicated in a number of neurological disorders, including schizophrenia, depression, and Alzheimer's disease. Herein we describe the discovery of potent GluN2A-selective NMDAR positive allosteric modulators (PAMs) starting from a high-throughput screening hit. Using structure-based design, we sought to increase potency at the GluN2A subtype, while improving selectivity against related α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs). The structure-activity relationship of channel deactivation kinetics was studied using a combination of electrophysiology and protein crystallography. Effective incorporation of these strategies resulted in the discovery of GNE-0723 (46), a highly potent and brain penetrant GluN2A-selective NMDAR PAM suitable for in vivo characterization.Entities:
Mesh：
Substances：
Year: 2016 PMID： 26919761 DOI： 10.1021/acs.jmedchem.5b02010
Source DB: PubMed Journal: J Med Chem ISSN： 0022-2623 Impact factor: 7.446